Roche Holding AG (XSWX:ROG) Research & Development

: CHF14,200 Mil (TTM As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Research & Development is the aggregate amount of research and development expenses during the year. Roche Holding AG's Research & Development for the six months ended in Dec. 2023 was CHF7,282 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was CHF14,200 Mil.

Roche Holding AG Research & Development Historical Data

The historical data trend for Roche Holding AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

12,774.00

13,009.00

14,799.00

15,225.00

14,200.00

Roche Holding AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															7,689.00	6,516.00	8,709.00	6,918.00	7,282.00

Roche Holding AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF14,200 Mil.

Roche Holding AG (XSWX:ROG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Roche Holding AG Research & Development Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (XSWX:ROG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBY:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.